DonCorleone77 Posted - 8 hours ago

$CNTA Morgan Stanley upgrades Centessa on 'best-in-class' potential of ORX750 Morgan Stanley upgraded Centessa to Overweight from Equal Weight with a price target of $26, up from $11. The firm had been "cautiously optimistic heading" into the Phase 1 readout based on safety signals seen with competing candidates in the space, but it now contends following the recent report of topline ORX750 Phase 1 results in healthy volunteers that the data "remove the largest overhang on the orexin 2 field and confirm it has potential to be best-in-class for treating narcolepsy." The firm updated its model and now includes market models for ORX750 in narcolepsy type 2 and idiopathic hypersomnia, the analyst noted.

basscat12 Posted - 17 hours ago

$DASH $PRLD $CNTA Pre-Market Mash-Up, page 4, Highlighted Analyst Activity, courtesy @TheTradeXchange , the Best Squawk On The Street, and presented with @Vegas1 to help prepare for today's market!

AnaChart Posted - 3 days ago

$CNTA https://anachart.com/wp-content/uploads/ana_temp/1726491703_soc-img.jpg

tradingtwenty Posted - 6 days ago

$CNTA has trended 21 times in the past 24 hours (based on 5 minute intervals). Latest press release on Sep 12, 2024 10:34 PM: Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares Link: https://tradingtwenty.com/news/620806/centessa-pharmaceuticals-announces-pricing-of-upsized-225000000-public-offering-of-american-depositary-shares

DonCorleone77 Posted - 6 days ago

$CNTA Centessa 15.25M share Spot Secondary priced at $14.75 The deal size was increased to 15.2M shares from 10.9M and priced below last closing price of $15.10. Goldman Sachs, Leerink, Evercore ISI, Guggenheim and BMO Capital acted as joint book running managers for the offering.

insiderbuyingselling Posted - 1 week ago

$CNTA new insider selling: 30000 shares. http://insiderbuyingselling.com/?t=CNTA

Stock_Titan Posted - 1 week ago

$CNTA Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares https://www.stocktitan.net/news/CNTA/centessa-pharmaceuticals-announces-pricing-of-upsized-225-000-000-nzivvvv3kw2a.html

StockInvest_us Posted - 1 week ago

Signal alert: $CNTA - Overbought Trend Short (Overvalued) https://stockinvest.us/l/qS6ND51Dl4

Stock_Titan Posted - 1 week ago

$CNTA Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares https://www.stocktitan.net/news/CNTA/centessa-pharmaceuticals-announces-150-000-000-proposed-public-65fqu0xjmriq.html

Thestocktraderhubzee Posted - 1 week ago

$CNTA Guggenheim Maintains Buy on Centessa Pharmaceuticals, Raises Price Target to $24

30DeltaSpy Posted - 1 week ago

$CNTA $5 billion dollar narcolepsy opportunity

1UpOnWallStreet Posted - 1 week ago

$CNTA Good buy here. Reversal now.

Will2ride1 Posted - 1 week ago

$CNTA congrats if you followed 🍻

GetVector Posted - 1 week ago

Vector Intelligence (VI) is an algorithm designed to predict potential outsized intraday moves. VI will select up to 4 stocks per day. Today's VI stocks: $CNTA, $VRDN.

DonCorleone77 Posted - 1 week ago

$CNTA Centessa announces interim data from ongoing Phase 1 trial of ORX750 Centessa Pharmaceuticals announced positive interim data from an ongoing Phase 1 trial of its highly potent and selective orexin receptor 2 agonist, ORX750, in acutely sleep-deprived healthy volunteers. ORX750 showed clinically meaningful and statistically significant improvements in mean sleep latency at the first two doses evaluated in the Maintenance of Wakefulness Test, MWT, compared to placebo. More specifically, the 2.5 mg dose was shown to restore normative wakefulness2 with a mean sleep latency of 32 minutes as measured by the MWT. ORX750 was also shown to have a favorable safety and tolerability profile with no observations of frequently reported on-target adverse events, AEs, associated with other OX2R agonists, and no cases of hepatotoxicity or visual disturbances across all three dose levels tested, as of the data cutoff date.1 Based on the interim data, the Company plans to rapidly advance ORX750 into Phase 2 studies in patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia beginning in the fourth quarter of 2024.

briefingcom Posted - 1 week ago

Gapping up: $AVO +21.1% $CNTA +15.2% $VRDN +12.7% $MTRX +8.3% $ORCL +8.2%

Thestocktraderhubzee Posted - 1 week ago

$CNTA Centessa Pharmaceuticals Announced Interim Data From An Ongoing Phase 1 Trial Of ORX750, In Acutely Sleep-deprived Healthy Volunteers, Showing Clinically Meaningful And Statistically Significant Improvements In Mean Sleep Latency At The First Two Doses Evaluated Vs. Placebo

Stock_Titan Posted - 1 week ago

$CNTA Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers https://www.stocktitan.net/news/CNTA/centessa-announces-positive-interim-phase-1-clinical-data-with-its-0e5y8o18asqn.html

AnaChart Posted - 1 week ago

$CNTA https://anachart.com/wp-content/uploads/ana_temp/1725886890_soc-img.jpg

PenkeTrading Posted - 2 weeks ago

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Centessa Pharmaceuticals PLC ADR. Is that bullish or bearish? $CNTA #CNTA #nasdaq #tradingsignals #technicalanalysis

QuantData Posted - 08/28/24

We have identified an unusual $CNTA block that expires on September 20, 2024 with a strike price of $15.00 5,000 CALL contracts with a price of $1.20 (Bid) were sold at a $600,000 premium. The price of $CNTA at the time of execution (12:35 PM ET) was $13.60

DonCorleone77 Posted - 08/27/24

$CNTA Centessa to present non-human primate data for ORX142 at Sleep Europe 2024 Centessa Pharmaceuticals announced that preclinical data from a non-human primate study of ORX142, a highly potent and selective orexin receptor 2 agonist being developed to address excessive daytime sleepiness in select neurological, neurodegenerative, and psychiatric disorders, has been accepted for a late- breaking poster presentation at the 27th Congress of the European Sleep Research Society being held September 24-27, 2024, in Seville, Spain. The poster presentation will feature, for the first time, robust preclinical data demonstrating that low doses of ORX142 promoted wakefulness in non-human primates in a highly predictive and translational model. "ORX142 is the second drug candidate from our growing pipeline of potentially best-in-class OX2R agonists that has shown significant activity in promoting wakefulness at very low doses in highly predictive and translational preclinical models," said Saurabh Saha MD PhD, Chief Executive Officer of Centessa. "We believe these non-human primate data are compelling as they demonstrate the potential for ORX142, a highly potent and novel OX2R agonist, to alleviate excessive daytime sleepiness in select neurological, neurodegenerative, and psychiatric disorders with no significant loss of orexin. We are thrilled to be sharing these preclinical data in a late-breaking presentation at Sleep Europe 2024."

Stock_Titan Posted - 08/27/24

$CNTA Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) https://www.stocktitan.net/news/CNTA/centessa-pharmaceuticals-announces-late-breaking-poster-presentation-buuuc13w75ph.html

FlynancialAnalyst Posted - 1 month ago

$CNTA ... this one's special Following latest data, Pct of all funds long shares is now at record highs as its rise continues $20+ on deck

Thestocktraderhubzee Posted - 1 month ago

$CNTA Oppenheimer Reiterates Outperform on Centessa Pharmaceuticals, Maintains $14 Price Target

Stock_Titan Posted - 1 month ago

$CNTA Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024 https://www.stocktitan.net/news/CNTA/centessa-pharmaceuticals-reports-financial-results-and-business-3cakklbz6hvk.html

FlynancialAnalyst Posted - 1 month ago

$CNTA with some fantastic follow thru on volume! $XBI leaders wants $20+ DD ^^ in thread above all the same

Wigglyick Posted - 1 month ago

$CNTA Centessa Pharma, developing therapies for unmed needs in a variety of areas. @FlynancialAnalyst has highlighted this stock a number of times and it has a great chart. So stop drooling into your pillow and do some DD.

FlynancialAnalyst Posted - 1 month ago

$CNTA $1.16B mc $XBI #HiddenGem (only 167 watchers on Stocktwits) with a low volume rinse into rising 10/40 wk SMAs Pct of all funds long shares is at record highs Short float % is at record lows TrendEdge.app/asset/CNTA

NVDAMillionaire Posted - 07/30/24

$CNTA Centessa Pharmaceuticals (CNTA): A Promising Biotech Poised for Transformative Breakthroughs http://beyondspx.com/2024/07/30/centessa-pharmaceuticals-cnta-a-promising-biotech-poised-for-transformative-breakthroughs/